Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: A multicenter, multinational, non-randomized, non-controlled Latin American study

Pharmacology

Volumn 68, Issue 2, 2003, Pages 89-95

  Islas Andrade, Sergio ^a,b   Revilla Monsalve, Maria Cristina ^a   Martínez de Hurtado, Evelyn ^a   Chacín, Luis F ^a   Caminos, Quenemari R ^a   Yupanqui, Hernán ^a   López, Gloria ^a   De La Torre, Walter ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Insulin secretion; Postprandial hyperglycemia; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; NATEGLINIDE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNOLOGY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN LIKE ACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA;

BLOOD GLUCOSE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LATIN AMERICA; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 0037266022     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069534     Document Type: Article

References (28)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-1431.
2. Islas-Andrade S, Revilla-Monsalve MC: Concepto y clasificación; in Islas-Andrade S, Lifshitz GA (eds): Diabetes Mellitus, ed 2. New York, McGraw-Hill, 1999, pp 13-14.
3. Hanefeld M, Bouter KP, Dickinson S, Guitard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23:202-207.
4. Kelly D: Approaches to preventing prandial hyperglycemia excursions. Curr Opin Endocrinol Diabetes 1996;6(suppl):7-11.
5. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794.
6. Avignon A, Radauceau A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control in type 2 diabetes. Diabetes Care 1997;20:1822-1826.
7. Mahler RJ, Adler ML: Type 2 diabetes mellitus: Update on diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab 1999;84:1165-1171.
8. Sato V, et al: Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-(trans-4-isopropylcyclohexyl-carbonyl)-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991;12:58-59.
9. ATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharma-col Exp Ther 2000;293:444-452.
10. De Sousa CJ, Russo P, Lozito R, Dunning B: Comparative effects of A-4166, sulphonylureas and repaglinide on meal-induced glucose excursions in normal rats (abstract). Diabetologia 1997;40:45.
11. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T: Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-iso-propylcyclohexane-carbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 1997;120:137-145.
12. Karara AH, Dunning BE, McLeod JF: The effect of food on the oral bioavailability and pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999;39:172-179.
13. Lebrun P, Malaisse WJ: Cationic and secretory effects of glimepiride and glibenclamide in perifused rat islets. Pharmacol Toxicol 1992;70:357-360.
14. Wallum BJ, Kahn SE, McCulloch DK, Porte D: Insulin secretion in the normal and diabetic human; in Alberti KG, De Fronzo RA, Keen H, Zimmet P (eds): International Textbook of Diabetes mellitus. New York, Wiley & Sons, 1992, pp 285-301.
15. Calles-Escandón J, Robbins DC: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987;36:1167-1172.
16. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988;37:736-744.
17. Butler PC, Rizza RA: Contribution to post-prandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991;40:73-81.
18. Mitrakou A, Kelly D, Mokan M: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-29.
19. Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care 1998;21:1236-1239.
20. ++ influx. Endocrinology 1994;134:1395-1400.
21. Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C: Nateglinide improves glycaemic control when added to metformin monotherapy: Results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002;4:177-186.
22. Hirschberg Y, Pietri AO, Karara AH, McLeod JF: Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23:349-353.
23. Kalbag JB, Walter YH, Nedelman JR, McLeod JF: Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placebo. Diabetes Care 2001:24:73-77.
24. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-988.
25. Kikuchi M, Kosaka K: Reduced postprandial hyperglycemia by A-4166 compared to voglibose in NIDDM subjects in Japan (abstract). Diabetes 1977;26(suppl 1):333.
26. Uto Y, Teno S, Iwamoto Y, Omori Y, Takizawa T: Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. Metabolism 2002;51:20-24.
27. Kahn SE, Montgomery B, Howell WM, Ligueros-Saylan M, Hsu C, Devineni D, McLeod JF, Horowitz AD: Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes (abstract). Diabetes 2000;49(suppl 1):113.
28. Levine M, Burns MJ: The pharmacology and toxicology of nateglinide. Int J Med Toxicol 2001;4:25-33.